Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Bayer Initiates Phase I Trial of Innovative Targeted Radionuclide Therapy, 225Ac-PSMA-Trillium, in Advanced Metastatic Prostate Cancer

NextEdge Admin

15 May 2024

2 min 40 sec

Metastatic Prostate Cancer,mCRPC,radiation

Bayer has announced the commencement of dosing in a Phase I clinical study for 225Ac-PSMA-Trillium (BAY 3563254), a novel targeted alpha therapy aimed at treating advanced metastatic castration-resistant prostate cancer (mCRPC). This investigational candidate, utilizing actinium-225, features a unique PSMA-targeting small molecule with a customized albumin-binding component. The study, identified as NCT06217822, will focus on assessing the safety, tolerability, and efficacy of 225Ac-PSMA-Trillium.

Fred Saad, MD, FRCS, Professor and Chairman of Surgery at the University of Montreal, expressed the high unmet need for precision therapy options in mCRPC. He highlighted the potential of 225Ac-PSMA-Trillium to address this need effectively. Bayer’s Dominik Ruettinger, M.D., Ph.D., emphasized the strategic importance of targeted radionuclide therapy in precision oncology, especially for patients with treatment-resistant disease. The company aims to leverage the unique design of 225Ac-PSMA-Trillium to provide significant benefits for patients with metastatic prostate cancer.

Despite significant advancements in prostate cancer treatment, mCRPC remains a major challenge, with Bayer reaffirming its commitment to innovation across all stages of the disease. The introduction of 225Ac-PSMA-Trillium at the AACR Annual Meeting and the subsequent Phase 0 clinical imaging and dosimetry study underscore Bayer’s dedication to advancing medical solutions for prostate cancer patients.

Targeted alpha therapy represents a promising approach in oncology, delivering alpha particle radiation directly to tumors while potentially minimizing damage to surrounding healthy tissues. Bayer, as a global leader in life sciences, aims to drive sustainable development and positive impact through its innovative products and services. In fiscal 2023, the company’s focus on R&D and commitment to quality and reliability remained steadfast, reflecting its mission to improve health and well-being worldwide.